Bristol's Pravachol (pravastatin) reduces MI risk by 31%, West of Scotland study reports.
BRISTOL-MYERS SQUIBB's PRAVACHOL REDUCES NONFATAL MI AND CHD DEATH BY 31%, from 7.9% to 5.5%, compared to placebo in men with hypercholesterolemia and no history of myocardial infarction, according to results of the West of Scotland Coronary Prevention Study reported Nov. 15 at the American Heart Association annual meeting in Anaheim and published in the Nov. 16 issue of The New England Journal of Medicine. The study, presented by James Shepherd, MD, University of Glasgow, also found that Pravachol (pravastatin) reduced the risk for heart attack alone compared to placebo by 31%, from 6.5% to 4.6%.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth